Pharming Group NV
AEX:PHARM

Watchlist Manager
Pharming Group NV Logo
Pharming Group NV
AEX:PHARM
Watchlist
Price: 0.8735 EUR -0.8% Market Closed
Market Cap: 592.5m EUR
Have any thoughts about
Pharming Group NV?
Write Note

Net Margin
Pharming Group NV

-6.2%
Current
2%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6.2%
=
Net Income
-17.8m
/
Revenue
285.7m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
NL
Pharming Group NV
AEX:PHARM
592.7m EUR
-6%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
309B USD
9%
US
Amgen Inc
NASDAQ:AMGN
141B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD
0%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
134.4B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-14%
Country NL
Market Cap 592.7m EUR
Net Margin
-6%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 309B USD
Net Margin
9%
Country US
Market Cap 141B USD
Net Margin
13%
Country US
Market Cap 116B USD
Net Margin
0%
Country US
Market Cap 103.5B USD
Net Margin
-5%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 134.4B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36B EUR
Net Margin
-14%
No Stocks Found

Pharming Group NV
Glance View

Market Cap
592.7m EUR
Industry
Biotechnology

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The company is headquartered in Leiden, Zuid-Holland and currently employs 321 full-time employees. The firm is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The firm's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

PHARM Intrinsic Value
1.1978 EUR
Undervaluation 27%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-6.2%
=
Net Income
-17.8m
/
Revenue
285.7m
What is the Net Margin of Pharming Group NV?

Based on Pharming Group NV's most recent financial statements, the company has Net Margin of -6.2%.